Jove
Visualize
Contact Us

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.2K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.2K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

4.2K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
4.2K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.0K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.0K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.6K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

6.4K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Gender affirming hormone therapy and its immunological implications.

Frontiers in immunology·2026
Same author

Measuring thyroid-stimulating hormone receptor antibodies using the IMMULITE<sup>®</sup> 2000 TSI assay is better than using the BRAHMS TRAK assay in an unselected clinical population, but both perform worse than expected: a real-world retrospective observational study.

Thyroid research·2026
Same author

Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultation.

Vaccine·2026
Same author

Patient safety and predictors for subsequent healthcare contact after self-care referral from Swedish ambulance services: a retrospective cohort study.

BMC emergency medicine·2026
Same author

Older adults as active research partners: protocol for an umbrella review.

BMJ open·2026
Same author

Brain fatigue in Graves' disease: symptoms and presentation of a possible mechanism at the cellular level.

European thyroid journal·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 21, 2025

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.2K

β1-adrenergic and Muscarinic Acetylcholine Type 2 Receptor Antibodies are Increased in Graves' Hyperthyroidism and

Karin Tammelin1, Anna Lundgren2,3, Mats Holmberg1,4

  • 1Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.

Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association
|January 12, 2021
PubMed
Summary

Autoantibodies targeting the β1-adrenergic and muscarinic acetylcholine type 2 receptors are elevated in Graves' disease patients and decrease with treatment. However, these autoantibodies did not correlate with cardiac function as measured by N-terminal pro-brain natriuretic peptide levels.

More Related Videos

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.1K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.8K

Related Experiment Videos

Last Updated: Nov 21, 2025

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.2K
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.1K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.8K

Area of Science:

  • Endocrinology
  • Immunology
  • Cardiology

Background:

  • Graves' disease is an autoimmune disorder affecting the thyroid.
  • Cardiovascular complications are common in Graves' disease.
  • G-protein-coupled receptors (GPCRs) play crucial roles in cardiovascular function.

Purpose of the Study:

  • To investigate the association between autoantibodies targeting cardiovascularly relevant GPCRs and cardiac function in Graves' disease.
  • To assess the levels of autoantibodies against β1-adrenergic, muscarinic acetylcholine type 2, and angiotensin II type 1 receptors.
  • To evaluate the correlation with N-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of heart function.

Main Methods:

  • Enzyme-linked immunosorbent assays (ELISAs) were used to measure IgG autoantibodies against specific GPCRs in 60 premenopausal women with Graves' disease.
  • NT-proBNP levels and cardiac symptoms were assessed during hyperthyroidism and after antithyroid treatment.
  • Thyroid-healthy controls were included for comparison.

Main Results:

  • Patients with Graves' disease exhibited significantly higher levels of autoantibodies against β1-adrenergic and muscarinic acetylcholine type 2 receptors compared to controls.
  • These autoantibody levels decreased after antithyroid treatment but remained elevated compared to controls.
  • NT-proBNP levels were elevated in hyperthyroidism, normalized post-treatment, and did not correlate with the measured autoantibodies.

Conclusions:

  • Autoantibodies against β1-adrenergic and muscarinic acetylcholine type 2 receptors are prevalent in Graves' disease and responsive to treatment.
  • Despite the decrease with treatment, these autoantibodies did not show a direct correlation with NT-proBNP levels, suggesting complex interactions with cardiac function.
  • The potential autoimmune impact on cardiac function in specific patient subpopulations warrants further investigation into the functional properties of these autoantibodies.